21
Participants
Start Date
June 12, 2021
Primary Completion Date
December 11, 2023
Study Completion Date
December 11, 2023
LAE005 + Afuresertib + Nab-Paclitaxel
LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
The first affiliated hopsital of bengbu medical college, Bengbu
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Sun Yat-sen Memorial Hospital, Guangzhou
Sir RunRun Shaw Hospital Zhejiang University School of Medicine, Hangzhou
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Laekna Limited
INDUSTRY